Algert Global LLC Purchases 7,761 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Algert Global LLC increased its stake in Medpace Holdings, Inc. by 18.4%, now owning 49,918 shares valued at approximately $15.21 million.
• Barclays and Robert W. Baird both raised their price target for Medpace, with new targets set at $450 and $490, respectively, while three analysts downgraded the stock to a "sell" rating.
• CEO August J. Troendle sold over 48,000 shares of Medpace stock for approximately $21.9 million, indicating a 4.80% reduction in his holdings.

Algert Global LLC grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 18.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,918 shares of the company's stock after buying an additional 7,761 shares during the period. Medpace makes up 0.4% of Algert Global LLC's holdings, making the stock its 20th biggest position. Algert Global LLC owned 0.17% of Medpace worth $15,210,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in MEDP. Whittier Trust Co. increased its position in Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after buying an additional 35 shares during the period. Colonial Trust Co SC lifted its position in Medpace by 150.0% during the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after purchasing an additional 105 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Medpace during the first quarter worth about $60,000. Assetmark Inc. lifted its position in Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after purchasing an additional 43 shares during the period. Finally, True Wealth Design LLC lifted its position in Medpace by 52.7% during the fourth quarter. True Wealth Design LLC now owns 258 shares of the company's stock worth $86,000 after purchasing an additional 89 shares during the period. Institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

Several brokerages have commented on MEDP. Mizuho boosted their target price on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Barclays boosted their target price on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. William Blair reissued a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft boosted their target price on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. Finally, Robert W. Baird boosted their target price on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Medpace has a consensus rating of "Reduce" and a consensus price target of $406.60.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.14, for a total transaction of $3,376,050.00. Following the transaction, the vice president directly owned 57,500 shares in the company, valued at approximately $25,883,050. This represents a 11.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin M. Brady sold 12,000 shares of the stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer owned 6,000 shares in the company, valued at $2,725,380. The trade was a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,788 shares of company stock worth $51,018,354. Company insiders own 20.30% of the company's stock.

Medpace Stock Performance

Shares of Medpace stock traded down $0.77 on Tuesday, hitting $462.14. The stock had a trading volume of 323,418 shares, compared to its average volume of 728,171. The stock has a 50 day moving average of $369.30 and a 200 day moving average of $332.71. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $501.30. The firm has a market capitalization of $12.98 billion, a P/E ratio of 34.36, a PEG ratio of 2.91 and a beta of 1.42.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The business had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.